In addition, we applied this TYR-catalytic platform to activate anti-cancer prodrugs in situ through the CuAAC reaction, sensitizing drug-resistant melanoma to chemotherapeutics both in vitro and in vivo. The gene discussed is TYR; the disease is cancer.